Anrotinib is usually taken as 8-12mg once daily for 2 weeks and is mainly used for malignant tumors such as lung cancer, adenoidal soft tissue sarcoma, and clear cell sarcoma.
Anrotinib is a targeted drug that inhibits tumor growth by inhibiting the activity of vascular endothelial growth factor receptor tyrosine kinase.
Anrotinib is taken as an oral medication, 8~12mg per dose for 2 weeks and 1 week off. Each course of treatment is 21 days.
The current NDA-approved indications include: advanced or metastatic non-small cell lung cancer that has progressed or recurred after receiving at least 2 prior systemic chemotherapies; it can also be used in patients with adenoid soft tissue sarcoma, clear cell sarcoma, and advanced soft tissue sarcoma who have received other treatments. It may also be used for small cell lung cancer that has progressed or recurred after receiving chemotherapy.
The most common adverse reactions to Anrotinib include fatigue, weight loss, high blood pressure, sinus tachycardia, diarrhea, abdominal pain,, nausea, decreased food, hyperglycemia, and musculoskeletal pain.
This drug is not suitable for pregnant and nursing women. Cancer patients should use this drug properly under the guidance of a clinical oncologist.